Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease

Bibliography

• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140(6):1785-94
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42(12):1118-25
   PubMed Web of Science ®Google Scholar
• Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120(3):622-35
   PubMed Web of Science ®Google Scholar
• Dineson L, Travis S. Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2(1):39-47
   PubMed Web of Science ®Google Scholar
• Breese E, Michie C, Nicholls SW, et al. Tumour necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106(6):1455-66
   PubMed Web of Science ®Google Scholar
• Murch S, Braegger C, Walker-Smith J, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9
   PubMed Web of Science ®Google Scholar
• Crohn’s disease: management in adults, children and young people. NICE clinical guideline 152. 2012. Available from: guidance.nice.org.uk/cg152 [Last accessed 2 August 2014]
   Google Scholar
• Rutgeerts P, Malchow H, Vatn MH, et al. Mucosal healing in Crohn’s disease patients is associated with reduction in hospitalisations and surgeries. Gastroenterology 2002;123:43
   Web of Science ®Google Scholar
• Infliximab and Adalimumab in Crohn’s disease. NICE clinical guideline 187. 2010. Available from: guidance.nice.org.uk/ta187 [Last accessed 2 August 2014]
   Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Eng J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Assche GV, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142(5):1102-11
   PubMed Web of Science ®Google Scholar
• Colombel JF. Infliximab in Crohn’s disease translating landmark data into clinical practice. Satellites 2009;6-8
   Google Scholar
• Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. national cooperative Crohn’s disease study. Gastroenterology 1976;70(3):439-44
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980;1(8167):514
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. groupe d’Etudes therapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 1989;30(7):983-9
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138(2):463-8
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease results from a norwegian population based cohort. Gastroenterology 2007;133(2):412-22
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care 1992;30(6):473-83
   PubMed Web of Science ®Google Scholar
• Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96(3):804-10
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. canadian Crohn’s relapse prevention trial. Am J Gastroenterol 1996;91(8):1571-8
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Panaccione R, Higgins PD, et al. The london position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106(2):199-212
   PubMed Web of Science ®Google Scholar
• Antakia R, Shorthouse AJ, Robinson K, et al. Combined modality treatment for complex fistulating perianal Crohn’s disease. Colorectal Dis 2013;15(2):210-16
   PubMed Web of Science ®Google Scholar
• Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical reatment of fistulising perianal Crohn’s disease. Aliment Pharmacol Ther 2014;40(7):741-9
   PubMed Web of Science ®Google Scholar
• UK IBD audit 2006. Available from: https://www.rcplondon.ac.uk/projects/ibdauditround1 [Last accessed 26 August 2014]
   Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142(1):63-70
   PubMed Web of Science ®Google Scholar
• Nelson AL. Antibody fragments: hope and hype. MAbs 2010;2(1):77-83
   PubMed Web of Science ®Google Scholar
• Weir AN, Nesbitt A, Chapman AP, et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 2002;30(4):512-16
   PubMedGoogle Scholar
• Refusal assessment report for cimzia. european medicines agency evaluation of medicines for human use. 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000740/WC500070613.pdf [Last accessed 28 August 2014]
   Google Scholar
• Lemke. Foye’s medical chemistry. 7th edition. Wolters Kluwer; 2012
   Google Scholar
• Chames P, Regemmortel MV, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor. Inflamm Bowel Dis 2007;13(11):1323-32
   PubMed Web of Science ®Google Scholar
• Eissner G, Kirchner S, Lindner H, et al. Reverse signalling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000;164(12):6193-8
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research application number: BLA 125160/0 pharmacology review. 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000_PharmR_P1.pdf [Last accessed 11 July 2014]
   Google Scholar
• Baker M, Stringer F, Stephens P. Pharmacokinetic properties of the anti-tumour necrosis factor agent certolizumab pegol. Ann Rheum Dis 2006;65(Suppl 2):175
   Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348(1-2):36-41
   PubMed Web of Science ®Google Scholar
• Herrington-Symes AP, Farys M, Khalili H, et al. Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol 2013;4:689-98
   Google Scholar
• Veronese FM. PEGylated protein drugs: basic science and clinical applications. Birkhäuser; 2009
   Google Scholar
• Kumar GT, Prakash NJ, Laxmi N, et al. Biotechnology based drug delivery by PEGylation method. IJRAP 2011;2(1):95-102
   Google Scholar
• Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013;6(4):269-93
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen O, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8(7):600-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: results from the PRECiSE 4 study. Clin Gastroenterol Hepatol 2010;8(8):696-702
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther 2004;20(11-12):1337-46
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005;129(3):807-18
   PubMed Web of Science ®Google Scholar
• Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol 2011;4(6):375-89
   PubMedGoogle Scholar
• Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62(2):201-8
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31(1):92-101
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12(3):423-31
   PubMed Web of Science ®Google Scholar
• Da W, Zhu J, Wang L, et al. Efficacy and safety of certolizumab pegol for Crohn’s disease: a systematic review and meta-analysis. Adv Ther 2013;30:541-53
   PubMed Web of Science ®Google Scholar
• Nikfar S, Ehteshami-Afshar S, Abdollahi M. Is certolizumab pegol safe and effective in the treatment of patients with moderate to severe Crohn’s disease? a meta-analysis of controlled clinical trials. Iran Red Crescent Med J 2013;15(8):668-75
   Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Wisniewska N, et al. Tumour necrosis factor-É antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci 2013;9(5):765-79
   PubMed Web of Science ®Google Scholar
• Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease. Aliment Pharmacol Ther 2009;29:605-14
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 2014;39(12):1349-62
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):644-59
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D’Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. Int J Colorectal Dis 2008;23:289-96
   PubMed Web of Science ®Google Scholar
• Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn’s disease. Am J Gastroenterol 2009;104(8):1976-83
   PubMed Web of Science ®Google Scholar
• Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;5(4):549-58
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108(8):1268-76
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2013; Epub ahead of print
   Web of Science ®Google Scholar
• van Vollenhoven R, Smolen J, Schiff M, et al. Safety update on certolizumab pegol (CZP) in patients with active rheumatoid arthritis (Ra). Rheumatology 2010;49:I102-3
   Web of Science ®Google Scholar
• Van Assche G, Lewis JD, Lichtenstein GR, et al. The london position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: safety. Am J Gastroenterol 2011;106:1594-602
   PubMed Web of Science ®Google Scholar
• Stephens S, Brown D, Nesbitt A, et al. Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated fab’ fragment in rats. J Crohn’s Colitis 2007;1:43
   Google Scholar
• Porter C, Kopotsha T, Smith B, et al. No significant transfer of certolizumab compared with IgG in the perfused human placenta in vitro. Ann Rheum Dis 2010;69:210
   PubMedGoogle Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3):286-92
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Fed Regist 1980;44:37434-67
   Google Scholar
• Reinisch W. Management of inflammatory bowel disease: lessons learned over decades. Satellites 2009;1-2
   Google Scholar
• Rutgeerts P, Vermeire S, Assche GV. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56(4):453-5
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Ardizzone S, Porro GB. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease. Core Evid 2008;2(3):209-29
   PubMedGoogle Scholar
• Center for drug evaluation and research application number: BLA 125160/0 summary review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000_SumR.pdf [Last accessed 11 July 2014]
   Google Scholar